Rapamycin's 2009 Mouse Result and the Human Evidence Gap
The Wikipedia Timeline of aging research records 2009 as the year rapamycin was shown to extend mouse lifespan; human evidence remains limited to survey studies and a single 48-week trial in healthy adults.
In 2009, rapamycin (sirolimus), an FDA-approved immune-modulating drug, extended lifespan in mice. The Wikipedia Timeline of aging research records this result.
Our hypothesis: this experiment became the starting point for today's interest in rapamycin as a longevity candidate. The available data do not confirm that causal link, and the mouse result alone says nothing about human lifespan.
Human evidence remains limited: survey-based studies and a single 48-week randomized placebo-controlled trial in healthy adults. Low-dose intermittent use appeared relatively safe, with selected improvements in healthspan measures. Bioavailability depends on formulation, blood levels vary between individuals, and dosing requires individualized monitoring. Our sources do not specify which measures improved or by how much. The available data do not show that rapamycin extends human lifespan.
Sources
[1] Timeline of aging research - Wikipedia
This edge connects a specific historical landmark in aging research to the current state of rapamycin evidence, making the animal-to-human translation gap concrete and traceable.